benefits of glp 1 microdosing GLP-1 Microdosing, Brain Health & Alzheimer's Prevention Why GLP-1 Microdosing? A Closer

Substance Use Disorders: Clinical Evidence Heres a look at the evidence for specific substance use disorders: Alcohol Use Disorders: There are multiple studies showing a reduction in alcohol consumption in animals with the use of GLP-1RAs

(2015, August)

1 By comparison, the top-licensed doses of Mounjaro and Wegovy produced average weight losses of 22.5% (SURMOUNT-1) and 20.7% (STEP UP), respectively

It is worth emphasizing that Phase 2 data involves smaller sample sizes, and the full safety profile of retatrutide will become clearer as Phase 3 trials progress

The FDA approves at 27 with comorbidities

Combined with reduced calories from Retatrutide, mood effects may amplify